<br />
RESPIRATORY<br />
EMJ Respir. 2020 Suppl 1 • emjreviews.com<br />
INSIDE<br />
Integrating Type 2 Biologics in the<br />
Management of Uncontrolled Severe<br />
Asthma: The Importance of Lung<br />
Function in Disease Control<br />
Integrating Type 2 Biologics in the Management of<br />
Uncontrolled Severe Asthma: The Importance of<br />
Lung Function in Disease Control<br />
This symposium took place on 30th September 2019, as part of the 29th<br />
European Respiratory Society (ERS) Congress in Madrid, Spain<br />
Chairpeople: Klaus F. Rabe1,2<br />
Speakers: Marc Humbert,3 Michael Wechsler4<br />
1. Lung Clinic Großhansdorf, Großhansdorf, Germany<br />
2. University of Kiel, Kiel, Germany<br />
3. South Paris University, Paris, France<br />
4. National Jewish Health, Denver, Colorado, USA<br />
Disclosure: Prof Rabe received speaker’s honoraria from AstraZeneca, Be<a title="EMJ Respiratory. 2020 Suppl 1 page 1" href="http://viewer.zmags.com/publication/4c4042a2?page=1"> RESPIRATORY EMJ Respir. 2020 Suppl 1 • emjreviews</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 2" href="http://viewer.zmags.com/publication/4c4042a2?page=2"> Integrating Type 2 Biologics in the Management of</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 3" href="http://viewer.zmags.com/publication/4c4042a2?page=3"> recommend considering add-on of Type 2-targeted b</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 4" href="http://viewer.zmags.com/publication/4c4042a2?page=4"> those with normal FEV at baseline (≥80%), those </a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 5" href="http://viewer.zmags.com/publication/4c4042a2?page=5"> IL-4, IL-13, and IL-5 Are Key Cytokineis</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 6" href="http://viewer.zmags.com/publication/4c4042a2?page=6"> Key Type 2 Cytokines IL-4, IL-13, and IL-5 in the</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 7" href="http://viewer.zmags.com/publication/4c4042a2?page=7"> and airway hyper-responsiveness. Clinically, this</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 8" href="http://viewer.zmags.com/publication/4c4042a2?page=8"> In patients with inadequately control</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 9" href="http://viewer.zmags.com/publication/4c4042a2?page=9"> Dupilumab: Effect on OCS Use, Lung Function, and </a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 10" href="http://viewer.zmags.com/publication/4c4042a2?page=10"> 1% with placebo), and the same for eosinophilia (</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 11" href="http://viewer.zmags.com/publication/4c4042a2?page=11"> accelerated decline in lung function in adult-ons</a>
<a title="EMJ Respiratory. 2020 Suppl 1 page 12" href="http://viewer.zmags.com/publication/4c4042a2?page=12"> subgroups in the Phase 3 LIBERTY 74. ASTH</a>